Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Current Deferred Revenue (2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Current Deferred Revenue for 4 consecutive years, with $4.3 million as the latest value for Q3 2025.

  • Quarterly Current Deferred Revenue changed N/A to $4.3 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Sep 2025, changed N/A year-over-year, with the annual reading at $119000.0 for FY2011, 44.39% down from the prior year.
  • Current Deferred Revenue for Q3 2025 was $4.3 million at Lexicon Pharmaceuticals, down from $17.5 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $45.0 million in Q1 2025, with the low at $4.3 million in Q3 2025.